Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Nurmijarvi, Finland Clinical Trials

A listing of Nurmijarvi, Finland clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

The study aims to evaluate the antibody persistence post primary vaccination with active control, safety and immunogenicity of a booster dose uncontrolled post primary vaccination during different phases: Persistence phase: Long-term persistence 6, 7, 8, 9 and 10 years after primary vaccination with MenACWY-TT or Meningitec or Mencevax ACWY, in ...

Phase

9.13 miles

Learn More »

Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children

Healthy children who were vaccinated 3 years earlier at 12 to 23 months of age in study MET54 (NCT03205358) are eligible for enrollment. All participants will receive a single booster dose of MenACYW conjugate vaccine on Day 0. Immunogenicity will be assessed pre-vaccination and 30 to 44 days after vaccination. ...

Phase

9.13 miles

Learn More »

Efficacy Safety and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults

This randomized, observer-blind, placebo-controlled multicenter, Phase 3 study will be conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins expressed as VLPs for the 2017-2018 influenza virus strains. Approximately ...

Phase

9.89 miles

Learn More »

Immunogenicity and Safety of Sci-B-Vac to Engerix-B in Adults 18 Years Old and Superiority in Adults 45 Years Old.

This study is a double-blind randomized controlled trial designed to establish the non-inferiority of Sci-B-Vac compared to Engerix-B in adults 18 years old and the superiority of Sci-B-Vac compared to Engerix-B in adults 45 years old. Study subjects will be randomized 1:1 to receive either a total of 3 injections ...

Phase

9.89 miles

Learn More »